Sort
82,697 grants matching “vaccine development”
Host-pathogen interactions during hospital adaptation of MRSA
$821,192Bo Shopsin · New York University School Of Medicine · R01 · FY2021 · AI
Core--Animal model
$821,175Thomas W North · J. David Gladstone Institutes · P01 · FY2007 · AI
Single-Cell Analysis of the HIV/SIV Reservoir
$821,117Dan H. Barouch · Beth Israel Deaconess Medical Center · R01 · FY2021 · AI
Single-Cell Analysis of the HIV/SIV Reservoir
$821,117Dan H. Barouch · Beth Israel Deaconess Medical Center · R01 · FY2024 · AI
Single-Cell Analysis of the HIV/SIV Reservoir
$821,117Dan H. Barouch · Beth Israel Deaconess Medical Center · R01 · FY2023 · AI
Single-Cell Analysis of the HIV/SIV Reservoir
$821,117Dan H. Barouch · Beth Israel Deaconess Medical Center · R01 · FY2022 · AI
HIV/AIDS Therapeutic and Non-vaccine Prevention Clinical Research
$821,096National Institute Of Allergy And Infectious Diseases · Y01 · FY2013 · AI
Expanding the use of Tetrahymena as a protein expression platform
$820,959Paul Colussi · Tetragenetics, Inc. · R44 · FY2015 · GM
Evolution of T cell immunity in blood and tissues over childhood
$820,875Donna L Farber · Columbia University Health Sciences · U01 · FY2022 · AI
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies
$820,861Justin Richard Bailey · Johns Hopkins University · R01 · FY2023 · AI
North Carolina Seronet Center for Excellence
$820,801Ralph S Baric · Univ Of North Carolina Chapel Hill · U54 · FY2024 · CA
Infant Immunoprophylaxis against a Primate Lentivirus
$820,779Ruth Margrit Ruprecht · Dana-Farber Cancer Inst · R37 · FY2008 · AI
Institutional Career Development Core
$820,725Kelly A Gebo · Johns Hopkins University · KL2 · FY2022 · TR
Determinants of Neutralization Breadth in Early HIV-1 Infection
$820,677Cynthia Ann Derdeyn · Emory University · R01 · FY2014 · AI
Determinants of Neutralization Breadth in Early HIV-1 Infection
$820,677Cynthia Ann Derdeyn · Emory University · R01 · FY2016 · AI
Determinants of Neutralization Breadth in Early HIV-1 Infection
$820,677Cynthia Ann Derdeyn · Emory University · R01 · FY2015 · AI
Innate and early B cell responses to V. cholerae
$820,657Jason B Harris · Massachusetts General Hospital · R01 · FY2014 · AI
Impact of HIV, oral microbiome and mycobiome on oral HPV persistence
$820,582Robert D. Burk · Albert Einstein College Of Medicine · R01 · FY2023 · DE
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
$820,478Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Immunologic and Metabolic Profiles of T cells that control diverse HCV infections
$820,384Andrea L Cox · Johns Hopkins University · U19 · FY2023 · AI
ESTABLISHMENT/MAINTENANCE OF BIOMEDICAL RESEARCH COLONY
$820,281University Of Louisiana At Lafayette · U42 · FY2000 · RR
Developmental Research Projects
$820,229Herbert P. Schweizer · Colorado State University · U54 · FY2012 · AI
A novel nanochannel system for sustained delivery of Tenofovir Alafenamide Fumarate and Emtricitabine for HIV pre-exposure prophylaxis
$819,857Alessandro Grattoni · Methodist Hospital Research Institute · R01 · FY2016 · AI
Developing small molecule therapeutics for Ebola hemorrhagic fever virus
$819,724Arnab Basu · Microbiotix, Inc · R01 · FY2011 · AI
Manufacturing and Toxicology Studies of DNA and Protein Vaccines
$819,711Gary R Ostroff · Univ Of Massachusetts Med Sch Worcester · U19 · FY2009 · AI